Patients must not have received a live attenuated vaccination within  days prior to sub-study registration
Live vaccination is not allowed for at least  weeks prior to the start of AMG  treatment, during treatment, and until end of last study dose
Vaccination with any live virus vaccine within  weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Has received a live vaccine within  days prior to the first dose of study drug; seasonal influenza vaccination is permitted excluding the nasal spray formulation
Vaccination with any live virus vaccine within  weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Vaccination with a live vaccine <  days prior to the start of treatment
Received live or attenuated vaccination within  days prior to the start of NMA-LD
Live vaccination within the last  days
Vaccination with a live vaccine a minimum of  days prior to the start of treatment
Have received any live vaccination within  days of first dose of study drug
Vaccination with a live vaccine a minimum of  days prior to the start of treatment
Vaccination with live vaccines within  days prior to the start of Cycle 
Vaccination with a live vaccine within  days of the initiation of treatment
Live attenuated vaccination administered within  days prior to randomization.
Vaccination with live vaccines within  days prior to start of treatment
have received any recent (within  days prior to randomization) live virus vaccination
Vaccination within  weeks of enrollment (except for annual flu vaccine).
Patients must not have received a live attenuated vaccination within  days prior to sub-study registration
Patients must not have received a live attenuated vaccination within  days prior to RE-TREATMENT registration
Vaccination with a live vaccine within  days prior to treatment
Vaccination with a live virus vaccine within  days prior to Day  of Cycle 
Vaccination with live vaccines within  days prior to randomization
Live-virus vaccination within  days prior to day  of protocol therapy
Vaccination with a live vaccine a minimum of  days prior to the start of treatment
Vaccination with a live vaccine <  days prior to the start of treatment
Vaccination with a live vaccine a minimum of  days prior to study treatment
Vaccination with a live vaccine within  days of the initiation of treatment
Prior vaccination with BCG for tuberculosis disease
Vaccination with a live vaccine within  days prior to randomization
Subjects who have received live virus vaccination within the  weeks prior to planned initiation of study treatment
Vaccination with a live vaccine within  days prior to randomization
Live vaccination within  weeks of the first dose of avelumab
Vaccination with a live vaccine a minimum of  days prior to randomization
Meningococcal vaccine(s) prior to LFG treatment if prior vaccination cannot be confirmed. The choice of vaccine(s) should take into account the serotypes prevalent in the geographic areas in which study patients will be enrolled. In case vaccination is not possible or will result in an unfavorable risk benefit ratio as judged by the investigator, vaccination can be postponed until deemed likely to be effective.
Patients < years old should receive vaccination for the prevention of S. pneumoniae and H. influenzae type b prior to LFG administration. In case vaccination is not possible or will result in an unfavorable risk benefit ratio as judged by the investigator, vaccination can be postponed until deemed likely to be effective.
Vaccination with a live vaccine a minimum of  days prior to the start of treatment
Vaccination with a live-virus vaccine up to  weeks prior to onset of study treatment.
Vaccination with a live vaccine a minimum of  weeks prior to study enrollment
Patients must not previously have received the Prevnar  pneumococcal vaccination; NOTE: previous vaccination with Pneumovax (PCV) is permitted but must have been at least  days prior to registration
Vaccination with live vaccines within  days prior to treatment
Vaccination with a live vaccine a minimum of  days prior to the start of Cycle 
Vaccination with live attenuated vaccine within  days prior to day  of PROSTVAC-V/F administration or vaccination with a killed vaccine within  days prior to day  of PROSTVAC-V/F
has practiced adequate contraception for  days prior to vaccination, and
has practiced adequate contraception for  days prior to vaccination, and
Have received a live vaccination within  days of study start.